vs
Side-by-side financial comparison of Evolent Health, Inc. (EVH) and Inspire Medical Systems, Inc. (INSP). Click either name above to swap in a different company.
Evolent Health, Inc. is the larger business by last-quarter revenue ($496.2M vs $204.6M, roughly 2.4× Inspire Medical Systems, Inc.). On growth, Evolent Health, Inc. posted the faster year-over-year revenue change (2.6% vs 1.6%). Over the past eight quarters, Inspire Medical Systems, Inc.'s revenue compounded faster (2.2% CAGR vs -12.4%).
Magellan Health Inc., is an American for-profit managed health care company and subsidiary of Centene that focuses on special populations and other specialty areas of healthcare. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. It ranked 390 on the Fortune 500 in 2021.
Inspire Medical Systems, Inc. is a medical technology firm that develops, manufactures and commercializes implantable neurostimulation solutions for obstructive sleep apnea. Its core product serves patients intolerant to CPAP therapy, with main markets across North America, Europe, and select Asia-Pacific regions, operating in sleep medicine and otolaryngology segments.
EVH vs INSP — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $496.2M | $204.6M |
| Net Profit | $-26.6M | — |
| Gross Margin | 16.9% | 86.5% |
| Operating Margin | — | 13.0% |
| Net Margin | -5.4% | — |
| Revenue YoY | 2.6% | 1.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $496.2M | $204.6M | ||
| Q4 25 | $468.7M | $269.1M | ||
| Q3 25 | $479.5M | $224.5M | ||
| Q2 25 | $444.3M | $217.1M | ||
| Q1 25 | $483.6M | $201.3M | ||
| Q4 24 | $646.5M | $239.7M | ||
| Q3 24 | $621.4M | $203.2M | ||
| Q2 24 | $647.1M | $195.9M |
| Q1 26 | $-26.6M | — | ||
| Q4 25 | $-429.1M | $136.1M | ||
| Q3 25 | $-20.9M | $9.9M | ||
| Q2 25 | $-19.9M | $-3.6M | ||
| Q1 25 | $-64.6M | $3.0M | ||
| Q4 24 | $-22.8M | $35.2M | ||
| Q3 24 | $-23.1M | $18.5M | ||
| Q2 24 | $1.6M | $9.8M |
| Q1 26 | 16.9% | 86.5% | ||
| Q4 25 | 20.7% | 86.6% | ||
| Q3 25 | 20.8% | 85.8% | ||
| Q2 25 | 22.6% | 84.0% | ||
| Q1 25 | 21.2% | 84.7% | ||
| Q4 24 | 11.7% | 85.0% | ||
| Q3 24 | 13.0% | 84.1% | ||
| Q2 24 | 16.5% | 84.8% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -87.1% | 17.1% | ||
| Q3 25 | 0.2% | 4.3% | ||
| Q2 25 | -0.3% | -1.5% | ||
| Q1 25 | -0.3% | -0.7% | ||
| Q4 24 | -2.9% | 13.3% | ||
| Q3 24 | -2.6% | 7.0% | ||
| Q2 24 | 1.2% | 2.6% |
| Q1 26 | -5.4% | — | ||
| Q4 25 | -91.6% | 50.6% | ||
| Q3 25 | -4.4% | 4.4% | ||
| Q2 25 | -4.5% | -1.7% | ||
| Q1 25 | -13.4% | 1.5% | ||
| Q4 24 | -3.5% | 14.7% | ||
| Q3 24 | -3.7% | 9.1% | ||
| Q2 24 | 0.2% | 5.0% |
| Q1 26 | — | $-0.39 | ||
| Q4 25 | $-3.76 | $4.57 | ||
| Q3 25 | $-0.24 | $0.34 | ||
| Q2 25 | $-0.44 | $-0.12 | ||
| Q1 25 | $-0.63 | $0.10 | ||
| Q4 24 | $-0.26 | $1.17 | ||
| Q3 24 | $-0.27 | $0.60 | ||
| Q2 24 | $-0.06 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $142.0M | $98.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $396.4M | $792.3M |
| Total Assets | $1.9B | $911.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $142.0M | $98.9M | ||
| Q4 25 | $151.9M | $308.3M | ||
| Q3 25 | $116.7M | $322.6M | ||
| Q2 25 | $151.0M | $300.9M | ||
| Q1 25 | $246.5M | $369.2M | ||
| Q4 24 | $104.2M | $445.5M | ||
| Q3 24 | $96.6M | $411.0M | ||
| Q2 24 | $101.3M | $439.7M |
| Q1 26 | $396.4M | $792.3M | ||
| Q4 25 | $415.2M | $781.2M | ||
| Q3 25 | $842.2M | $666.5M | ||
| Q2 25 | $896.0M | $677.8M | ||
| Q1 25 | $935.5M | $635.7M | ||
| Q4 24 | $1.0B | $689.7M | ||
| Q3 24 | $1.0B | $696.6M | ||
| Q2 24 | $1.1B | $638.1M |
| Q1 26 | $1.9B | $911.4M | ||
| Q4 25 | $1.9B | $907.3M | ||
| Q3 25 | $2.5B | $807.7M | ||
| Q2 25 | $2.5B | $802.2M | ||
| Q1 25 | $2.7B | $730.8M | ||
| Q4 24 | $2.5B | $808.4M | ||
| Q3 24 | $2.5B | $796.2M | ||
| Q2 24 | $2.5B | $728.4M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVH
| Performance Suite | $323.3M | 65% |
| Specialty Technology and Services Suite | $80.8M | 16% |
| Administrative Services | $49.6M | 10% |
| Cases | $42.6M | 9% |
INSP
Segment breakdown not available.
